Bio – Talk Bio

National Resilience, Layoffs, Gene Therapy, Bluebird Bio, Durham/ North Carolina, Biotech Industry, CDMO (Contract Development and Manufacturing Organization)

Novo Nordisk and Variant Bio Collaborate on Metabolic Disease Research, Focusing on Diverse Populations

4 months ago talkbio0Tagged benefit-sharing program, Bio, Diversity, Genetic Research, geographic population, Metabolic Diseases, Nordisk, Variant, VB-Inference platform

Novo Nordisk, Variant Bio, Metabolic disease, Genetic research, Diverse populations, VB-Inference platform, Benefit-sharing program

KdT Ventures Launches New Biotech Startup to Develop NGM Bio’s Rare Disease Drug Candidate NGM313

4 months ago talkbio0Tagged Bio, Biotechnology, Drug Development, KdT, NGM, NGM313, Phase 2 trial, Ventures

KdT Ventures, NGM Bio, NGM313, Rare Disease, Biotechnology, Drug Development, Phase 2 Trial

GSK Exits Biotechnology Innovation Organization (BIO) for 2025, Joining Takeda, UCB, and Others

5 months ago talkbio0Tagged AbbVie, AppTec, Bio, Biotechnology, Drug Industry, lobbying, Pfizer, SmithKline Beecham, Takeda, TNFRSF19 gene, UCB, WuXi

GSK, BIO, Biotechnology Innovation Organization, Takeda, UCB, Pfizer, WuXi AppTec, AbbVie, pharmaceutical industry, trade group, lobbying

Lyell Immunopharma Acquires ImmPACT Bio to Bolster CAR T-cell Therapy Pipeline

6 months ago talkbio0Tagged Autoimmune Diseases, Automobiles, Bio, Biotechnology, Cancer Therapeutic Procedure, Lyell Immunopharma, pipeline acquisition, T-cell therapy

Lyell Immunopharma, ImmPACT Bio, CAR T-cell therapy, pipeline acquisition, biotechnology, cancer treatment, autoimmune diseases

Tolerance Bio Secures $17.2M Seed Funding to Develop Thymus-Targeted Cell Therapies

6 months ago talkbio0Tagged Allogeneic, Bio, Cell Therapy, Drug Tolerance, immune-mediated diseases, Plant seeds, thymus extracts

Tolerance Bio, cell therapy, thymus, immune-mediated diseases, seed funding, allogeneic iPSC-based therapy

Vanqua Bio Advances Experimental Parkinson’s Therapy with VQ-101, Bolsters Leadership Team

7 months ago talkbio0Tagged Accumulation, alpha-Synuclein, Bio, Clinical Trials, GBA gene, GCase, GCase activator, Lysosomal dysfunction, Neurodegenerative Disorders, Parkinson 's disease, Vanqua, VQ-101

Vanqua Bio, VQ-101, Parkinson’s disease, GBA gene mutations, GCase activator, Neurodegenerative diseases, Clinical trials, Lysosomal dysfunction, Alpha-synuclein accumulation